1. Home
  2. XBIT vs LNSR Comparison

XBIT vs LNSR Comparison

Compare XBIT & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.36

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$6.00

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
LNSR
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.4M
69.1M
IPO Year
2015
2005

Fundamental Metrics

Financial Performance
Metric
XBIT
LNSR
Price
$2.36
$6.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
29.4K
113.9K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$58,435,000.00
Revenue This Year
N/A
$10.06
Revenue Next Year
N/A
$41.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9.24
52 Week Low
$2.09
$5.06
52 Week High
$3.61
$13.43

Technical Indicators

Market Signals
Indicator
XBIT
LNSR
Relative Strength Index (RSI) 46.97 55.40
Support Level $2.26 $5.33
Resistance Level $2.49 $6.34
Average True Range (ATR) 0.05 0.36
MACD 0.01 0.04
Stochastic Oscillator 29.59 65.17

Price Performance

Historical Comparison
XBIT
LNSR

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.

Share on Social Networks: